Company Overview - Company name is 基蛋生物科技股份有限公司, primarily engaged in the research, production, sales, and service of in vitro diagnostic reagents and instruments [1] - The company is recognized as a key high-tech enterprise under the National Torch Program and is a major supplier in the domestic in vitro diagnostic field, particularly in the POCT sector [1] Financial Performance - As of the latest quarterly report for Q1 2025, the company achieved revenue of 244 million yuan, representing a year-on-year decrease of 24.08% [1] - The net profit for the same period was 64.31 million yuan, down 25.24% year-on-year, with a sales gross margin of 77.15% [1] Market Position - The company's stock closed at 8.19 yuan, with a PE ratio of 20.57 times, while the average PE ratio for the medical device industry is 49.64 times [1][2] - The total market capitalization of the company is 4.154 billion yuan [1] Shareholder Information - As of March 31, 2025, the number of shareholders is 26,747, a decrease of 451 from the previous count, with an average holding value of 352,800 yuan per shareholder [1]

Core Viewpoint - The company held an online performance briefing on May 27, 2025, to discuss its 2024 annual and 2025 Q1 performance, addressing investor concerns and highlighting operational and financial conditions [1]. Group 1: Financial Performance - The company's gross margin for 2024 increased by 2.86 percentage points to 69.23%, attributed to supply chain management optimization and product structure adjustments, despite a decline in operating revenue [2]. - In Q1 2025, the company achieved operating revenue of 244 million yuan, with overseas conventional product revenue reaching 47 million yuan, a year-on-year increase of 66.51% [2]. Group 2: Business Strategy and Market Position - The company is responding to industry challenges such as centralized procurement and DRG policies by optimizing sales strategies and enhancing service systems to maintain stable business development [4]. - The Metis6000 fully automated biochemical immunoassay line targets secondary and lower-tier hospitals, with over 70% of installations in these facilities, indicating a clear market positioning strategy [4][5]. Group 3: Product Development and Innovation - The Metis7000 fully automated biochemical immunoassay line is in the trial production phase, aiming to enhance performance and cost-effectiveness, with a broad testing menu covering nearly 400 items [5]. - The company plans to further increase the proportion of its chemiluminescence business, which accounted for 26.72% of self-produced product revenue in 2024, growing by 31.14% year-on-year [4]. Group 4: International Expansion - The company has established a presence in 66 countries and regions, holding over 2,500 overseas registration certificates and product import permits, with a focus on expanding its market share in Europe, Asia, and Latin America [5].

证券代码：603387 证券简称：基蛋生物 公告编号：2025-022 基蛋生物科技股份有限公司 关于 2024 年度暨 2025 年第一季度业绩网上说明会 召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 基蛋生物科技股份有限公司（以下简称"公司"）于2025年5月27日 14:00-15:00在上证所信息网络有限公司上证路演中心平台（以下简称"上证路 演中心"）采用网络互动方式召开"基蛋生物2024年度暨2025年第一季度业绩说 明会"。关于本次业绩说明会的召开事项，公司已于2025年4月30日在《上海证 券报》及上海证券交易所网站上披露了《基蛋生物科技股份有限公司关于召开 2024年度暨2025年第一季度业绩说明会的公告》（公告编号：2025-013）。现将 有关事项公告如下： 一、本次说明会召开情况 2025年5月27日，公司董事长苏恩本先生、公司财务总监倪文先生、公司董 事会秘书刘葱女士、公司独立董事万遂人先生、公司独立董事鞠熀先先生、公司 独立董事凌华女士出席了本次业绩说明会。公司就2024年度及20 ...

证券代码：603387 证券简称：基蛋生物 公告编号：2025-021 基蛋生物科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一) 股东大会召开的时间：2025 年 5 月 22 日 (二) 股东大会召开的地点：南京市六合区沿江工业开发区博富路 9 号基蛋生 物科技股份有限公司四楼会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 1、 公司在任董事9人，出席9人，董事孔婷婷、董事颜彬、董事倪文、独立董事 万遂人现场出席会议；董事长苏恩本、董事陶爱娣、董事苏恩奎、独立董事凌华、 独立董事鞠熀先因公出差，线上参会； 2、 公司在任监事3人，出席3人，监事会主席李靖、监事施佳、监事张武现场出 席会议； 3、 董事会秘书出席会议；其他高管列席会议。 二、 议案审议情况 审议结果：通过 表决情况： | 股东类型 | 同意 | | 反对 | | 弃权 | | | --- | --- | ...

南京市鼓楼区集庆门大街 270 号苏宁环球国际中心 43 层 电话：025-85803866 传真：025-85803680 邮编：210003 北京国枫（南京）律师事务所 关于基蛋生物科技股份有限公司 2024 年年度股东大会的 法律意见书 国枫律股字[2025]H0026 号 致：基蛋生物科技股份有限公司（贵公司） 北京国枫（南京）律师事务所（以下简称"本所"）接受贵公司的委托，指派律师 出席并见证贵公司 2024 年年度股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称 "《股东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证 券法律业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简 称"《证券法律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《基 蛋生物科技股份有限公司章程》（以下简称"《公司章程》"）的规定，就本次会议的 召集与召开程序、召集人资格、出席会议人员资格、会议表决程序及表决结果等事宜， 出具本法律意见书 ...

Core Points - The company Getein Biotech, Inc. is preparing for its 2024 Annual General Meeting (AGM) scheduled for May 22, 2025, in Nanjing, China, where various proposals will be discussed and voted on [1][2][3]. Proposal Summaries - **Proposal 1**: Approval of the 2024 Annual Report and its summary, which reflects the company's operational performance for the year [5][6]. - **Proposal 2**: Approval of the 2024 Board of Directors' Work Report, detailing the board's activities and responsibilities throughout the year [6][7]. - **Proposal 3**: Approval of the 2024 Supervisory Board Work Report, which outlines the supervisory activities and compliance with regulations [17][18]. - **Proposal 4**: Approval of the 2024 Financial Settlement Report, including audited financial statements and key financial metrics [21][22]. - **Proposal 5**: Discussion of the profit distribution plan for 2024, which will be based on the company's financial performance [1][5]. - **Proposal 6**: Approval of the remuneration for directors and senior management, ensuring alignment with company performance [1][5]. - **Proposal 7**: Approval of the remuneration for supervisors, maintaining transparency and accountability [1][5]. - **Proposal 8**: Authorization for the use of idle funds for investment and financial management, aimed at optimizing asset utilization [1][5]. - **Proposal 9**: Approval for the company and its subsidiaries to apply for comprehensive credit lines from banks, facilitating financial flexibility [1][5]. - **Proposal 10**: Reappointment of the accounting firm for the annual audit, ensuring compliance and accuracy in financial reporting [1][5]. - **Proposal 11**: Expansion of the company's business scope and amendments to the Articles of Association, reflecting strategic growth initiatives [1][5]. - **Proposal 12**: Authorization for the Board to formulate and implement a mid-term dividend plan, enhancing shareholder returns [1][5]. Meeting Logistics - The AGM will combine in-person attendance and online voting, with specific time slots for participation [3][4]. - The meeting will be presided over by the Board of Directors, ensuring structured proceedings and adherence to legal requirements [3][4]. Financial Performance Overview - The company reported a revenue of approximately CNY 1.16 billion for 2024, a decrease of 14.93% from the previous year [21][22]. - Net profit attributable to shareholders was approximately CNY 223.64 million, down 20.06% year-on-year [21][22]. - The company’s total assets stood at approximately CNY 3.71 billion, reflecting a slight decrease of 1.70% compared to the previous year [21][22]. - The net asset value attributable to shareholders increased by 2.33% to approximately CNY 2.62 billion [21][22]. Governance and Compliance - The Board of Directors and Supervisory Board have conducted their duties in accordance with relevant laws and regulations, ensuring proper governance and oversight [17][18]. - The company has maintained a focus on improving internal controls and compliance, with regular audits and evaluations of financial practices [19][20].

基蛋生物科技股份有限公司 2024 年年度股东大会会议资料 基蛋生物科技股份有限公司 Getein Biotech,Inc. 2024 年年度股东大会 会议资料 中国 南京 二〇二五年 五月 基蛋生物科技股份有限公司 2024 年年度股东大会会议资料 基蛋生物科技股份有限公司 2024 年年度股东大会会议资料目录 | 序号 | 会议资料名称 | | --- | --- | | 1 | 基蛋生物科技股份有限公司 2024 年年度股东大会会议须知 | | 2 | 基蛋生物科技股份有限公司 2024 年年度股东大会会议议程 | | 3 | 基蛋生物科技股份有限公司 2024 年年度股东大会会议议案及听取的报告 | | 议案 1 | 关于公司《2024 年年度报告》及其摘要的议案 | | 议案 2 | 关于公司《2024 年度董事会工作报告》的议案 | | 议案 3 | 关于公司《2024 年度监事会工作报告》的议案 | | 议案 4 | 关于公司《2024 年度财务决算报告》的议案 | | 议案 5 | 关于公司 2024 年度利润分配方案的议案 | | 议案 6 | 关于公司董事、高级管理人员薪酬的议案 | | ...

Group 1 - The mayor emphasizes the importance of major projects as a stabilizing force for growth and development, urging all levels of government to prioritize project execution and expand effective investment [2] - The construction of the Nanjing North Station hub is highlighted as a significant project with high social attention, requiring coordinated efforts among various departments to overcome challenges and ensure quality [1] - The focus on the high-end chemical project at Jinling Petrochemical aims to enhance the development of the petrochemical industry towards high-end, intelligent, and green growth [1] Group 2 - The mayor calls for a strong organizational approach to project implementation, focusing on key indicators such as start-up rates and investment rates, to ensure timely problem resolution and effective project execution [2] - There is an emphasis on the need for precise and efficient service to meet project demands, ensuring resource allocation and support for enterprises [2] - The mayor encourages companies to focus on market demands and accelerate the application of innovative results to foster new growth points [1]

证券代码：603387 证券简称：基蛋生物 公告编号：2025-020 基蛋生物科技股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 股东持股的基本情况 南京爱基商务信息咨询有限公司（以下简称"南京爱基"）为基蛋生物科技 股份有限公司（以下简称"公司"或"基蛋生物"）的员工持股平台。截止本公 告披露日，南京爱基持有基蛋生物股份 17,547,819 股,占公司总股本的 3.46%。 以上股份来源为首次公开发行前持有的股份及上市后资本公积转增股本方式取 得的股份。 ? 减持计划的主要内容 ? 本次减持计划不包含公司实控人苏恩本先生在南京爱基持有的份额，在 本次减持计划中，苏恩本先生不以任何方式减持其在南京爱基间接持有的公司 股份。 一、减持主体的基本情况 股东名称 南京爱基商务信息咨询有限公司 控股股东、实控人及一致行动人 √是 □否 直接持股 5%以上股东 □是 √否 股东身份 | | 董事、监事和高级管理人员 | □是 | √否 | | --- | --- | ...

证券代码：603387 证券简称：基蛋生物 公告编号：2025-020 基蛋生物科技股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东持股的基本情况 南京爱基商务信息咨询有限公司（以下简称"南京爱基"）为基蛋生物科技 股份有限公司（以下简称"公司"或"基蛋生物"）的员工持股平台。截止本公 告披露日，南京爱基持有基蛋生物股份 17,547,819 股,占公司总股本的 3.46%。 以上股份来源为首次公开发行前持有的股份及上市后资本公积转增股本方式取 得的股份。 减持计划的主要内容 近日，公司收到股东南京爱基出具的《关于减持计划告知函》，股东南京爱 基计划通过集中竞价交易方式减持公司股份，减持数量不超过 666,625 股，占公 司总股本的比例为 0.1314%。 本次减持计划不包含公司实控人苏恩本先生在南京爱基持有的份额，在 本次减持计划中，苏恩本先生不以任何方式减持其在南京爱基间接持有的公司 股份。 | 股东名称 | 南京爱基商务信息咨询有限公司 | | | | ...